Decoy Therapeutics (NASDAQ:DCOY) Short Interest Down 78.5% in June

Decoy Therapeutics (NASDAQ:DCOY) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totaling 1,966 shares, a drop of 78.5% from the May 31st total of 9,158 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 18,536 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Decoy Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, June 12th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.00.

Decoy Therapeutics Trading Down 6.8%

DCOY stock traded down $0.40 during midday trading on Friday, reaching $5.52. The stock had a trading volume of 5,227 shares, compared to its average volume of 13,592. The firm has a fifty day simple moving average of $6.12. Decoy Therapeutics has a 52-week low of $4.32 and a 52-week high of $415.80. The firm has a market cap of $2.93 million, a PE ratio of -0.05 and a beta of 0.57.

Decoy Therapeutics (NASDAQ:DCOY) last posted its quarterly earnings results on Friday, May 8th. The company reported ($4.18) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Decoy Therapeutics will post -12.97 EPS for the current fiscal year.

About Decoy Therapeutics

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577.